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Key Points
Methylation analysis at ZAP-70 CpG+223 in CLL provides superior prognostic information vs
IGHV status or CD38 or ZAP-70 expression.
A pyrosequencing method for the feasible assessment of CpG+223 methylation in CLL samples is
provided.
Abstract
ZAP-70 methylation 223 nucleotides downstream of transcription start (CpG+223) predicts outcome in
chronic lymphocytic leukemia (CLL), but its impact relative to CD38 and ZAP-70 expression or
immunoglobulin heavy chain variable region (IGHV) status is uncertain. Additionally, standardizing ZAP-
70 expression analysis has been unsuccessful. CpG+223 methylation was quantitatively determined in 295
untreated CLL cases using MassARRAY. Impact on clinical outcome vs CD38 and ZAP-70 expression and
IGHV status was evaluated. Cases with low methylation (<20%) had significantly shortened time to first
treatment (TT) and overall survival (OS) (P < .0001). For TT, low methylation defined a large subset of
ZAP-70 protein-negative cases with significantly shortened TT (median, 8.0 vs 3.9 years for high vs low
methylation; hazard ratio [HR] = 0.43; 95% confidence interval [CI], 0.25-0.74). Conversely, 16 ZAP-70
protein-positive cases with high methylation had poor outcome (median, 1.1 vs 2.3 years for high vs low
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methylation; HR = 1.62; 95% CI, 0.87-3.03). For OS, ZAP-70 methylation was the strongest risk factor;
CD38 and ZAP-70 expression or IGHV status did not significantly improve OS prediction. A
pyrosequencing assay was established that reproduced the MassARRAY data (κ coefficient > 0.90). Thus,
ZAP-70 CpG+223 methylation represents a superior biomarker for TT and OS that can be feasibly
measured, supporting its use in risk-stratifying CLL.
Introduction
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia, and despite the introduction of
new therapies, remains a serious clinical challenge. Based upon the lack of survival advantage observed to
date with early treatment,  therapy for CLL is not initiated until symptoms or clinical signs develop.  The
increasing availability and diversity of novel agents makes it even more important to identify CLL patients
who are more likely to require aggressive intervention or who are more likely to respond to a given
therapy. The ability to predict time to first treatment (TT) has improved with the identification of
cytogenetic abnormalities [del(17p13.1), del(11q22.3), or complex karyotype], immunoglobulin heavy
chain variable region (IGHV) gene mutation status, or expression of 70-kDa ζ-chain associated protein
(ZAP-70) or CD38.  One of the earliest biomarkers identified in CLL was ZAP-70 expression, which is
associated with unmutated IGHV  and shorter TT and overall survival (OS).  The abnormal presence of
ZAP-70 protein in CLL cells impacts their biology via enhancement of B-cell receptor (BCR) signaling,
proliferation, and migration toward the tumor microenvironment.  The success to date of the BCR
pathway-targeting agents idelalisib  and ibrutinib  further underscores the importance of ZAP-70 in
CLL.
Despite the strong interest in measuring ZAP-70 expression to predict TT, reliable clinical assays for this
are problematic, making their use inapplicable to routine CLL patient care. Previously, we identified
differential methylation in CLL tumor cells of a single CpG dinucleotide 223 bp downstream of the
transcriptional start site (CpG+223) in exon 1 of ZAP-70. Methylation of this site was significantly
associated with a lack of ZAP-70 protein expression as well as increased TT, progression-free survival
(PFS), and OS.  However, only a subset of patients in that study had ZAP-70 expression data available,
preventing firm conclusions regarding the relative prognostic value of the 2 different ZAP-70 measures.
Additionally, the previous application of the MassARRAY technique for DNA methylation assessment,
although powerful and highly quantifiable,  is not readily translatable to a clinical laboratory. Addressing
these issues is necessary to bring ZAP-70 methylation analysis to practical use in CLL management.
Herein, we not only confirm our initial findings with CpG+223 methylation but substantially extend them
to demonstrate the relative superiority of this parameter for prognostication over ZAP-70 protein
expression, IGHV mutational status, and CD38 expression. Finally, we describe a simplified
pyrosequencing assay that can be applied for routine clinical use.
Methods
Patients and cells
Peripheral blood was obtained from asymptomatic, untreated CLL patients. All patients were enrolled on a
prospective natural history study of the CLL Research Consortium (CRC). All patients provided written,
informed consent for this study under institutional review board–approved protocols according to the
Declaration of Helsinki. Samples used were derived from 295 patients reported previously for prognostic
significance of ZAP-70 protein expression.  Samples were considered to be ZAP-70 and CD38
positive if the percentage of ZAP-70– or CD38-expressing CLL cells exceeded 20%. Here we used a 20%
cut point for CD38, as this is a standard cut point with most flow cytometric antigens assessed and has
been previously published.  However, we also report results of sensitivity analyses using the previously
reported cut points of 7%  and 30%.  IGHV mutational analysis was performed as described.  Cases
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with sequence homology of <98% vs germline sequence were considered mutated. Patient demographics
are summarized in Table 1.
Quantitative high-resolution DNA methylation analysis by MassARRAY
DNA methylation was assessed at single CpG units (consisting of 1 or more CpG dinucleotides) using the
MassCleave assay (Sequenom) as described.
Quantitative DNA methylation analysis by pyrosequencing
Genomic DNA (500 ng) was bisulfite-treated using the EZ DNA Methylation-Gold kit (Zymo). Bisulfite-
treated DNA (50 ng) was amplified in a polymerase chain reaction (PCR) with primers: ZAP70_FW: 5′-
TGGGAGATTTGGTAGAGGATGAA-3′; ZAP70_RV: 5′-
GTGCCAGGCTCAGGCCCTCCTAACTCCCAATTAATATTCTATCTT-3′; Universal: 5′-Biotin-
ATCTGTGCCAGGCTCAGGC-3′.
Thermal cycler conditions were: 95°C, 15 minutes; then 49 cycles of 95°C, 30 seconds; 57.5°C, 30
seconds; 72°C, 30 seconds; then 72° for 5 minutes using HotStarTaq (Qiagen). Pyrosequencing was
performed on a Pyromark Q96 MD instrument (Qiagen) with setting CDT0003 using 8 µL of PCR product
and sequencing primer ZAP70_SEQ 5′-ATGAGTGAGAAATTTTGG-3′ (0.3 µM) following the standard
Qiagen protocol with Qiagen Pyromark reagents, GE Streptavidin Sepharose beads (GE Healthcare), and
the PyroMark Q96 Vacuum Workstation. Nucleotides were diluted 1:2 in water. This same protocol was
used in an independent laboratory to confirm transferability of this method.
Clinical laboratory improvement amendment validated assay development
Pyrosequencing is becoming more commonly applied in the clinical setting for detection of disease-related
gene mutations or methylation (eg, MGMT, EGFR).  For this validated assay in a third, clinical
laboratory, the instrument used was a Pyromark ID (setting ID/MA0008) and 37 µL of PCR was
sequenced. Also, nucleotides in the pyrosequencing run for the ID instrument were used undiluted,
sepharose beads were increased from 2 µL to 3 µL, and sequencing primer was increased from 0.3 µM to
0.4 µM. All other conditions remained the same (detailed protocol in supplemental Materials, available on
the Blood Web site).
Statistical analysis
Associations between demographic and molecular features with ZAP-70 CpG+223 methylation levels
(<20% vs ≥20%) were tested using the Wilcoxon rank sum and Fisher exact tests for continuous and
categoric variables, respectively. TT was measured from the date of diagnosis until the date of first
treatment. Patients who were confirmed to have remained untreated were censored at the date last known
to be treatment-free. OS was measured from the date of diagnosis until the date of death, censoring
patients alive at last follow-up. Estimates of treatment-free proportions and OS were obtained by the
Kaplan-Meier method, and the log-rank test compared differences between survival curves. Proportional
hazards models were used to analyze the association of CpG+223 methylation with TT and OS when
adjusting for other molecular markers (IGHV status, expression of CD38 and ZAP-70). All tests were 2-
sided and statistical significance was set at α = 0.05. Concordance in methylation values measured by
pyrosequencing vs MassARRAY is shown graphically using Bland-Altman plots and quantified using
Lin’s concordance correlation coefficient.  The degree of agreement in classification of low and high
methylation levels between the 2 methods was evaluated using the Cohen κ coefficient.
Results
ZAP-70 CpG+223 methylation correlates with extended TT and OS
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Among the 295 patients included in this study, 263 were followed for TT and included in the analysis.
With a median follow-up of 3.9 years in 50 patients who had not yet started treatment, the estimated
median TT was 3.5 years (95% confidence interval [CI], 2.9-4.0). All patients were followed for OS. With
a median follow-up of 5.6 years among the 196 patients still alive, the estimated median OS was 11.0 years
(95% CI, 9.1-12.5). We confirmed that methylation of CpG+223 as a continuous variable was significantly
associated with both TT and OS (P < .0001 for both end points), as we reported previously.
Using the data-driven cut point of 15% previously identified,  we formed 2 prognostic groups based upon
methylation of CpG+223: <15% and ≥15%. As seen in supplemental Figure 1A, methylation of CpG+223
significantly discriminated TT (P < .0001), where the estimated median TT for those with low and high
methylation, respectively, was 2.9 years (95% CI, 2.0-3.3) vs 6.1 years (95% CI, 4.0-7.6). Likewise, the
estimated median OS was 9.0 years (95% CI, 7.9-10.1) in those with low methylation (supplemental
Figure 1B), significantly shorter than the 16.7 years (95% CI, 11.0-22.7) estimated for those with high
methylation. Collectively, we confirmed our previous findings that methylation of CpG+223 was highly
predictive of TT and OS for early-stage untreated CLL.
Cut point for CpG+223 methylation
In this data set, the median CpG+223 methylation value by MassARRAY was 9% and levels of
methylation ranged from 2% to 86%. When examining the distribution of CpG+223 methylation levels for
the entire cohort of patients in this study and in the previously published studies  (supplemental Figure
2A-B), a gap in the methylation values occurred between 20% and 25%, with sparseness in values also
between 55% and 65%. As CLL cell genomes are generally diploid,  we hypothesized that this distinct
trimodal distribution of ZAP-70 methylation values reflects the stable allelic methylation state in the entire
CLL cell population at this particular locus, as has been shown to occur in the CLL genome at large.
Thus, the first distinct break in the methylation values implies biological significance and may separate
cases with both alleles robustly unmethylated in almost all CLL cells from those with monoallelic or
biallelic methylation. Given that a data-driven, optimal cut point is subject to change depending on the
data set, a cut point with potential biological significance and robustness is appealing. Using a 20% cut
point based on the allelic methylation state of CpG+223, the 2 larger previously published data sets still
showed a strong significant association between methylation and TT, PFS, and OS (P < .0001;
supplemental Figure 3A-D). Therefore, this cut point was used in subsequent analyses presented herein.
Patient demographics are shown in Table 1. Neither age nor sex was associated with methylation status.
IGHV status and CD38 and ZAP-70 protein expression were measured on all patients and all were
associated with ZAP-70 CpG+223 methylation levels. IGHV unmutated disease, CD38 expression, and
ZAP-70 protein expression were more commonly and significantly observed in the ZAP-70 unmethylated
group (P < .0001 for all comparisons).
Prognostic value of CpG+223 methylation relative to IGHV status and CD38 and ZAP-70
protein expression with respect to TT
When applying the ZAP-70 methylation cutoff of 20% to form 2 prognostic groups, TT was significantly
longer for those with higher vs lower methylation levels (P < .0001, Table 2; Figure 1A), where the
median TT was 6.5 (95% CI, 5.4-9.0) and 2.9 (95% CI, 2.0-3.3) years, respectively. Similarly, patients
with IGHV mutated disease had longer TT compared with those with IGHV unmutated disease (P <
.0001), patients who were negative for CD38 expression had longer TT than those positive for CD38 (P <
.0001), and patients who were negative for ZAP-70 expression had longer TT compared with those who
were positive (P < .0001). Because all 4 of these biomarkers were strongly and significantly associated
with TT, we next evaluated the prognostic impact that CpG+223 methylation had on TT in the context of
the other 3 established biomarkers in the subgroups segregated by IGHV status and CD38 and ZAP-70
protein expression. Among each of the IGHV and CD38 subgroups (mutated/unmutated;
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positive/negative), those cases with higher CpG+223 methylation values had significantly extended TT
compared with those with lower methylation values (Figure 2A-B). In each setting, knowledge of
CpG+223 methylation status revealed a subgroup of patients who are typically considered lower risk
(IGHV mutated or CD38 negative), but who actually fared poorly with low methylation. Conversely,
knowledge of CpG+223 methylation status revealed a subgroup of patients who are typically considered
high risk (IGHV unmutated or CD38 positive), but who actually had an intermediate prognostic profile
with high methylation. A different pattern was observed when TT according to methylation status was
examined by ZAP-70 protein expression. In cases lacking ZAP-70 expression, high methylation was again
strongly protective (P < .0001, Figure 2C) with a median TT of 8.0 years (95% CI, 6.3-10.0) compared
with only 3.9 years (95% CI, 2.8-4.7) in those with low methylation. However, methylation had no
significant effect in those with ZAP-70 protein expression (P = .27, Figure 2C), where TT was short
regardless of methylation levels. A multivariable model for TT was fit including IGHV status, CD38
positivity and the interaction between CpG+223 methylation and ZAP-70 positivity. With all variables in
the model, only the interaction effect between CpG+223 methylation and ZAP-70 protein status was
statistically significant (P = .0007), whereas IGHV status and CD38 expression did not provide additional
prognostic information (2 degrees of freedom test, P = .27) (supplemental Table 1). When alternative cut
points (7% and 30%) for CD38 expression were investigated in sensitivity analyses, the importance of the
CpG+223 methylation and ZAP-70 positivity interaction effect did not change (P < .001); however, CD38
provided additional prognostic information independent of the interaction effect when using these cut
points (P = .046 and P = .043 for 7% and 30%, respectively).
Prognostic value of CpG+223 methylation for OS relative to IGHV status and CD38 and
ZAP-70 protein expression
The analysis conducted for TT was repeated for OS. As shown in Table 2, OS from diagnosis was
significantly longer with higher methylation (P < .0001), where the median OS was 17.5 (95% CI, 16.7–
not reached) and 9.1 (95% CI, 8.0-11.1) years for those with higher and lower methylation levels,
respectively (Figure 1B). Likewise, OS was longer for IGHV mutated patients (P < .0001), those lacking
CD38 expression (P = .13), and those lacking ZAP-70 protein expression (P < .0001). The impact of
methylation levels for each subgroup of patients segregated by IGHV status, CD38 expression, and ZAP-
70 positivity are shown in Figure 3A. In the IGHV and CD38 subgroups, similar patterns seen for TT were
observed for OS, where higher methylation levels tended to extend OS compared with lower levels. In
contrast to what was observed with TT, the effect of methylation on OS was not significantly different
according to ZAP-70 protein positivity (P = .57). Rather, methylation of CpG+223 was beneficial in both
ZAP-70–negative and –positive patients, albeit more so in the negative subgroup (Figure 3C).
In a multivariable model for OS, the 4 biomarkers jointly explained a significant amount of variability in
survival (overall test of significance, P < .0001); however, the prognostic information is shared among the
related biomarkers, leading to nonsignificant signals for each marker in the model individually
(supplemental Table 2). Given that CpG+223 methylation as a sole prognostic marker for OS was highly
statistically significant and is also the strongest of the 4 biomarkers associated with OS in the multivariable
model (hazard ratio [HR] = 0.52; 95% CI, 0.26-1.07; P = .07), it could be considered the dominant
biomarker of the 4 in predicting OS. Furthermore, with CpG+223 methylation in the model, IGHV status,
CD38 positivity, and ZAP-70 protein expression did not provide additional significant prognostic
information (3 degrees of freedom test, P = .31). Similar results were obtained regardless of the cut point
used for CD38 in sensitivity analyses.
Development of a feasible, quantifiable assay to measure CpG+223 methylation in clinical
samples
We next sought to convert the quantitative ZAP-70 methylation detection assay from MassArray to
pyrosequencing. We designed and validated anappropriate pyrosequencing protocol and compared
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pyrosequencing data obtained in 3 different laboratories (one clinical laboratory improvement amendment
[CLIA] approved) to each other and to data obtained previously by MassARRAY analysis. Direct
comparisons are shown in supplemental Figure 4A-C, whereas differences in the 2 measures can be seen
more clearly in Bland-Altman plots, shown in supplemental Figure 4D-F. In the CLIA-accredited and
College of American Pathologists-certified clinical molecular diagnostic laboratory, 5 replicates at 15
dilutions were analyzed. Methylation values by pyrosequencing tended to be overestimated at low
dilutions and underestimated at higher dilutions, but the average difference was near 0 (0.69), with a
standard deviation of 5%. In general, the concordance was substantial (concordance correlation coefficient,
ρ  = 0.98). Importantly, at a dilution level of 20%, the pyrosequencing values did not differ by >3%, with
the lowest value at 17% and the highest at 23%.
Concordance with pyrosequencing data for the patient samples was only moderate in laboratories 2 and 3
(ρ  = 0.92 and ρ  = 0.90, respectively) due to a small number of samples that had very different
methylation values by the 2 methods (supplemental Figure 4E-F). When categorized as having high and
low methylation levels based on the 20% cut point, both laboratories had high measures of agreement
between the 2 methods (second laboratory, κ coefficient = 0.95; third laboratory, κ coefficient = 0.91). In
the second laboratory, 98% of the samples were in agreement, with only 6 samples examined by
pyrosequencing miscalled as being more (n = 2) or less (n = 4) than 20% as initially identified on
MassARRAY. In the third laboratory, 96% of the samples were in agreement, with only 12 samples
examined by pyrosequencing miscalled as being more (n = 4) or less (n = 8) than 20% on MassARRAY
(these 12 included the 6 miscalled in the first laboratory). In summary, despite minor limitations in the
quantification of methylation as a continuous measure by pyrosequencing, the vast majority of patient
samples were correctly categorized as having high (≥20%) or low (<20%) levels of methylation in 2
independent laboratories. Further studies are needed to assess whether this high level of correct
classification is maintained across a broader range of laboratories.
Discussion
Here, we investigated a large CLL patient cohort not only to validate initial findings that ZAP-70
CpG+223 methylation shows strong prognostic relevance with respect to TT and OS,  but also,
importantly, to extend these studies to demonstrate the prognostic value of ZAP-70 methylation relative to
established CLL prognostic factors. The data set used here includes samples derived from one of the
reference studies examining protein expression of ZAP-70, along with the surrogate markers CD38
expression and IGHV mutation status, in conjunction with TT and OS.  In this larger sample set, we
identified a break in the methylation levels at 20% that provided similar and consistent results with our
previous work.  CLL cell populations generally exhibit a remarkably low level of overall intratumor
heterogeneity of DNA methylation patterns, which is associated with the presence of a high degree (up to
10% of total CpGs) of allele-specific methylation occurring genome-wide.  Thus, the observed distinct,
trimodal distribution is very likely a consequence of an allelic pattern of DNA methylation at this
particular locus, which is stably maintained in the entire CLL cell population, and the break at 20%
separates CLL patients lacking CpG+223 methylation from those who have monoallelic or biallelic
methylation. Indeed, CLL methylation patterns are highly stable over time, even following treatment.
The presence of such a stable DNA methylation pattern at the ZAP-70 promoter locus suggests a robust
clonal event occurring early during leukemogenesis. In practical terms, this permits reliable analysis of
archival samples, or those with suboptimal cell viability as frequently occurs in CLL sample procurement.
Investigation of this large, characterized sample set allowed us to demonstrate that ZAP-70 CpG+223
methylation discriminates clinical outcome as measured by TT and OS. Furthermore, this new study also
identified a large subset of ZAP-70 expression-negative cases (ie, expected to have a better prognosis) that
had low CpG+223 methylation levels and shortened TT and OS comparable to ZAP-70 expression-
positive cases. Thus, assessment of CpG+223 methylation improves risk stratification within what would
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be considered a favorable risk group. A small group (6%) of patients with higher levels of methylation
continued to express ZAP-70 protein and had particularly short TT. For OS, the significant modification of
ZAP-70 protein expression on the impact of CpG+223 methylation was not observed. Here, ZAP-70
methylation was the factor most strongly predictive of OS in a multivariable model that included IGHV
status and expression of CD38 and ZAP-70.
Although ZAP-70 methylation results typically coincide with ZAP-70 expression data, discordant cases do
occur as noted in “Results.” We observed a large proportion of cases with low ZAP-70 protein expression
that had low methylation levels and reduced TT; conversely, a small group of cases with highly methylated
CpG+223 continued to express ZAP-70 and had short TT. Reasons for discordant ZAP-70 protein
expression and methylation are uncertain, but could include alternative promoter regulation, divergent
CLL clones, hydroxymethylation of this site, or histone modifications,  and are currently under
investigation. Regardless, in practice, these data support first assessing methylation status, and then
considering protein analysis (if possible) for those cases exhibiting high levels of methylation; however,
the difficulties of assessing ZAP-70 protein expression levels in clinical samples unfortunately remain.
Corcoran and colleagues were the first to identify the relevance of ZAP-70 methylation.  Methylation of
the specific site in the Corcoran study was assessed using combined bisulfite restriction analysis, which is
dependent upon restriction enzyme activity at a single site, and accurate quantification is difficult.
Additionally, Chantepie et al performed pyrosequencing analysis of ZAP-70 methylation in CLL
investigating several alternative sites in intron 1,  reporting that methylation correlates with CD38
expression, IGHV mutation status, TT, and OS. Our findings significantly extend these observations and
refine the prognostic significance, focusing on a distinct CpG dinucleotide. To increase the applicability of
ZAP-70 methylation analysis, we also developed a new pyrosequencing method for ZAP-70 CpG+223, as
pyrosequencing is becoming increasingly available in clinical molecular laboratories. Transferability of
this pyrosequencing assay was verified, strong agreement in methylation classification into low and high
groups was confirmed, and standards for a CLIA-approved diagnostic test were developed that can be used
clinically for risk stratification.
Importantly, our prognostic abilities as well as our understanding of CLL biology will continue to evolve
as newly reported markers such as CD49d expression  are further validated and functionally
characterized. Additionally, the dramatic increase in discovery of novel mutations relevant to CLL disease
pathology is allowing improved disease classification and prognostication via the integration of different
genetic parameters, as proposed by Rossi et al.  These ongoing developments will require continued re-
evaluation of the prognostic value of ZAP-70 methylation in the context of other abnormalities, ideally to
develop tailored treatment strategies for each patient. As novel therapies targeting BCR signaling (eg,
ibrutinib, idelalisib) become more widely available, it will also be important to reinvestigate the prognostic
significance of ZAP-70 methylation compared with established prognostic markers, such as genomic
abnormalities detected by fluorescence in situ hybridization, in this context. Although it will likely be
many years before survival data are available with these targeted agents, we envision that ZAP-70
assessment will become even more relevant in the era of BCR-directed therapies, as ZAP-70 expression is
likely to be tightly connected to BCR signaling. Similarly, it will be valuable to investigate the molecular
mechanism by which CpG+223 methylation impacts ZAP-70 expression, and whether such a mechanism
may constitute a therapeutic target of its own. ZAP-70 methylation assessment has already been included
as part of a phase 1b/2 trial with ibrutinib,  and is now being integrated into the risk-classification process
for an ongoing phase 3 trial involving ibrutinib (NCT01886872 ) to allow its formal evaluation relative to
response to this highly effective agent.
In conclusion, we have validated and extended our previous study of the prognostic value of ZAP-70
methylation at CpG+223, demonstrated its overall superiority over ZAP-70 protein expression assessment,
28
29
30
31
32
33
34
7/5/2018 Validation of ZAP-70 methylation and its relative significance in predicting outcome in chronic lymphocytic leukemia
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC4125353/?report=printable 8/16
Go to:
Go to:
Go to:
Go to:
and adapted an assay that is transportable to clinical application. These results strongly support assessment
of ZAP-70 CpG+223 methylation as part of prospective analyses and risk stratification of CLL.
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Table 1
Demographic and molecular features for all patients and by ZAP-70 CpG+223 methylation
CLL marker data Overall, N =
295
Methylation <20%, n =
197
Methylation ≥20%, n =
98
P
CpG+223 methylation,
%
NA
 Median 9 6 49.5
 Range 2-86 2-19 24-86
Age, y .57
 Median 55 55 56
 Range 26-82 26-79 33-82
Sex, N (%) .50
 Male 204 (69) 139 (71) 65 (66)
 Female 91 (31) 58 (29) 33 (34)
IGHV, N (%) < .0001
 Mutated 91 (31) 21 (11) 70 (71)
 Unmutated (≥98%) 204 (69) 176 (89) 28 (29)
CD38, N (%) < .0001
 Negative 139 (47) 74 (38) 65 (66)
 Positive (≥20%) 156 (53) 123 (62) 33 (34)
ZAP-70, N (%) < .0001
 Negative 136 (46) 57 (29) 79 (81)
 Positive (≥20%) 159 (54) 140 (71) 19 (19)
NA, not applicable.
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Table 2
Kaplan-Meier estimates for TT and OS by risk factor
Biomarker TT OS
Median, y 95% CI Median, y 95% CI
Methylation, <20% 2.9 2.0-3.3 9.1 8.0-11.1
Methylation, ≥20% 6.5 5.4-9.0 17.5 16.7-NR
M-IGHV 6.3 4.5-8.0 16.7 12.1-22.7
U-IGHV 2.9 2.1-3.4 9.1 8.0-11.0
CD38 4.4 3.7-5.6 12.0 9.1-16.7
CD38 2.8 1.9-3.4 9.7 8.4-12.2
ZAP-70 5.5 4.2-6.9 16.7 12.1-22.7
ZAP-70 2.1 1.7-2.9 8.8 7.8-9.9
M-IGHV, IGHV mutated; NR, not reached; U-IGHV, IGHV unmutated.
−
+
−
+
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Figure 1
Open in a separate window
DNA methylation at CpG+223 segregates patients with different clinical outcome using a potentially biologically
meaningful cutoff of 20%. (A) Kaplan-Meier curves illustrate the time from diagnosis to first treatment of patients who
have CLL cells with lower levels of methylation (<20%) compared with those patients who have CLL cells with higher
levels of methylation (≥20%). (B) Kaplan-Meier curves illustrate the overall survival duration of patients who have CLL
cells with lower vs higher levels of methylation.
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Figure 2
Open in a separate window
Effect of methylation (<20% vs ≥20%) on time from diagnosis to first treatment in subgroups of patients
segregated by IGHV mutational status, CD38 expression, and ZAP-70 protein expression. (A) Methylation levels
segregate patients who are M-IGHV (P = .02) or U-IGHV (P = .02). (B) Methylation levels segregate patients who are
CD38 negative (P < .0001) or positive (P = .03). (C) Methylation levels segregate patients who are ZAP-70 negative (P <
.0001) but not patients who are ZAP-70 positive (P = .27). M-IGHV, IGHV mutated; U-IGHV, IGHV unmutated.
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Figure 3
Open in a separate window
Effect of methylation (<20% vs ≥20%) on OS from time of diagnosis in subgroups of patients segregated by IGHV
mutational status, CD38 expression, and ZAP-70 protein expression. (A) Methylation levels tend to segregate patients
who are M-IGHV (P = .03) or U-IGHV (P = .21). (B) Methylation levels tend to segregate patients who are CD38
negative (P < .0001) or CD38 positive (P = .11). (C) Methylation levels tend to segregate patients who are ZAP-70
negative (P = .006) or ZAP-70 positive (P = .19).
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